First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study

In this retrospective cohort study, we evaluated the drug therapies used for early rheumatoid (RA) and undifferentiated (UA) arthritis patients. From a nationwide register maintained by the Social Insurance Institution, information on sex, date of birth, and date of special medicine reimbursement de...

Full description

Saved in:
Bibliographic Details
Published in:BMC rheumatology 2020-07, Vol.4 (1), p.34-34, Article 34
Main Authors: Muilu, Paula, Rantalaiho, Vappu, Kautiainen, Hannu, Virta, Lauri J, Eriksson, Johan G, Puolakka, Kari
Format: Article
Language:English
Subjects:
Age
Antirheumatic drugs
Biologic therapy
Biological products
Clinical medicine
Disease modifying
Drug dosages
Drug therapy
Females
Patients
Rheumatoid arthritis
Undifferentiated arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this retrospective cohort study, we evaluated the drug therapies used for early rheumatoid (RA) and undifferentiated (UA) arthritis patients. From a nationwide register maintained by the Social Insurance Institution, information on sex, date of birth, and date of special medicine reimbursement decision for all new Finnish RA and UA patients between 2011 and 14 were collected, and their DMARD (Disease Modifying Antirheumatic Drug) purchases during the first year after the diagnosis were analyzed. A total of 7338 patients with early RA (67.3% female, 68.1% seropositive) and 2433 with early UA (67.8% female) were identified. DMARDs were initiated during the first month after the diagnosis to 92.0% of the patients with seropositive RA, 90.3% with seronegative RA and to 87.7% with UA (  
ISSN:2520-1026
2520-1026
DOI:10.1186/s41927-020-00127-6